Our Methodology
Cheemia’s methodology is built around a simple reality: the NHS adopts products when they solve real problems in ways the system can support.
We help pharmaceutical companies connect what their product offers with what the NHS actually needs. That means working inside how decisions are made, how services operate and how pressure is felt across the system, not running campaigns from the outside.
How we approach the NHS
We always start by understanding what is getting in the way.
Before anything is planned, we look at how a problem is handled today, where patients or clinicians experience friction, and what sits behind current decisions. This includes listening to healthcare professionals, medicines management teams and service leads.
That work creates a realistic picture of what would need to change for a product to move from approval to routine use.
What drives adoption
In the NHS, evidence on its own does not lead to uptake. What matters just as much is how a medicine fits into patient pathways, budgets, commissioning structures and day-to-day clinical practice.
We focus on the practical and system-level factors that influence whether something will be used, including who has the ability to enable progress and where decisions tend to stall.
This allows us to see early on whether adoption is possible and where effort should be directed.
Where to focus effort
One of the ways Cheemia works differently is that we do not treat every route as viable.
We use what we learn about the system to decide where engagement is likely to lead to change and where structural barriers make progress unlikely. That protects time, budget and relationships, and helps keep work focused on the places where patients are most likely to benefit.
Working with NHS teams
Our engagement with healthcare professionals is shaped by respect for their time and their reality.
We support conversations that relate to real clinical and service challenges, acknowledge capacity and budget pressures, and provide clarity rather than volume. This is why NHS teams are willing to engage with Cheemia. The conversations are grounded in what matters to them.
What this approach delivers
This approach helps pharmaceutical companies avoid wasted effort, understand where NHS barriers really sit, and communicate with greater relevance and credibility. It also increases the likelihood that patients gain access to appropriate treatments.
We work within the ABPI Code of Practice and NHS governance at all times, and we treat confidentiality and data protection as fundamental to how we operate.